Petros Pharmaceuticals, Inc.
Support and Resistance Levels
Past performance
News About PTPI
All events for PTPI
All deals for PTPI
Financial Ratios
Financial Statements
PTPI vs Sector & Peers
About Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York. Website petrospharma.com
Headquarters New York City, NY, US